MedTrace Logo

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

NCT00636090 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2013-12-04

No results posted yet for this study

Summary

The purpose of this study is to look at the genetic changes that RAD001 causes in prostate cancer cells and how those changes relate to patients' response to RAD001 treatment.

Conditions

  • Metastatic Hormone Refractory Prostate Cancer

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Duke University

    lead OTHER

Principal Investigators

  • Daniel J George, MD · Duke University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636090 on ClinicalTrials.gov